Aortic Valve Stenosis
Conditions
Brief summary
Current care randomized clinical trial comparing the CE marked Symetis ACURATE neo™ Aortic Bioprosthesis and ACURATE TF™ Transfemoral Delivery System with the CE marked Medtronic CoreValve Evolut R TAVI system (or any future CE-marked CoreValve versions).
Detailed description
Transcatheter aortic valve implantation (TAVI) is an established and valuable treatment option for patients with severe symptomatic aortic stenosis and at high surgical risk for aortic valve replacement. The use of TAVI is rapidly expanding worldwide and its indications are widening into intermediate and lower risk populations. However, device comparisons by use of randomized trials are scarce in particular for newer generation transcatheter valves. The Symetis ACURATE neo™, a self-expanding transcatheter valve delivered via transfemoral access, is a second-generation device that gained CE mark approval in June 2014. The SCOPE-II trial will compare the safety and performance of the Symetis ACURATE neo™ with the self-expanding Medtronic Evolut R system, a widely used and well-established transcatheter heart valve, which obtained CE mark in 8NOV2006 and HAS approval on 13JAN2015.
Interventions
DEVICESymetis ACURATE neo™ transfemoral TAVI system
Symetis ACURATE neo™ transfemoral TAVI system: Support frame made of nitinol, supra-annular processed tri-leaflet porcine pericardial valve and an outer skirt to mitigate paravalvular regurgitation (manufactured by Symetis SA, Ecublens, Switzerland).
DEVICEMedtronic CoreValve Evolut R TAVI System
Medtronic CoreValve Evolut R Transcatheter Aortic Valve Implantation (TAVI) System (or any future CE-marked Corevalve versions): The support frame is manufactured from nitinol, which has multilevel, self-expanding properties and is radiopaque. The bioprosthesis is manufactured by suturing valve leaflets and a skirt from porcine pericardium into a tri-leaflet configuration (manufactured by Medtronic CoreValve LLC, Santa Ana, USA).
Sponsors
Symetis SA
Ceric Sàrl
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
75 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient with severe symptomatic aortic stenosis defined by a mean aortic gradient \> 40 mmHg or peak jet velocity \> 4.0 m/s or an aortic valve area (AVA) \< 1cm2 or AVA indexed to body surface area (BSA) of \<0.6 cm2/m2 * Patient is symptomatic (heart failure with New York Heart Association (NYHA) Functional Class \> I, angina or syncope) * Patients are considered at high risk for mortality with conventional surgical aortic valve replacement as assessed by a Heart Team consisting of a cardiologist and surgeon or as confirmed by a logistic EuroSCORE I \> 20% and / or STS score \> 10%. * Aortic annulus diameter ranging from 21 to 26mm and perimeter rage from 66 - 81.7mm , based on ECG-gated multi-slice computed tomographic measurements. Findings of TTE, TEE and conventional aortography should be integrated in the anatomic assessment. * Arterial aorto-iliac-femoral axis suitable for transfemoral access as assessed by conventional angiography and/or multi-detector computed tomographic angiography (access vessel diameter ≥ 6mm) * Patient understands the purpose, the potential risks as well as benefits of the trial and is willing to participate in all parts of the follow-up * Patient age 75 years or older * Patient has given written consent to participate in the trial
Exclusion criteria
* Severely reduced left ventricular (LV) function (ejection fraction \<20%) * Pre-existing prosthetic heart valve in aortic and/or mitral position * Participation in another trial, which would lead to deviations in the preparation or performance of the intervention or the post-implantation management from this protocol * Severe coagulation conditions * Inability to tolerate anticoagulation therapy * Contraindication to contrast media or allergy to nitinol * Active infection, including endocarditis * Congenital aortic stenosis or unicuspid or bicuspid aortic valve * Non-valvular aortic stenosis * Hypertrophic obstructive cardiomyopathy * New or untreated echocardiographic evidence of intracardiac mass, thrombus, or vegetation * Non-calcific acquired aortic stenosis * Severe eccentricity of calcification * Anatomy not appropriate for transfemoral implant due to size, disease and degree of calcification or tortuosity of the aorta or ilio-femoral arteries * Severe mitral regurgitation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Composite of all-cause mortality or stroke rates | 1 year | The primary objective is to compare the composite of all-cause mortality or stroke rates at 1 year (powered for non-inferiority). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| All cause mortality at 30 days | 30 days | All cause mortality |
| Stroke at 30 days | 30 days | Stroke |
| Valve malpositioning at 30 days | 30 days | Valve malpositioning |
| Peri-procedural myocardial infarction at 30 days | 30 days | Peri-procedural myocardial infarction |
| Cardiac Tamponade at 30 days | 30 days | Cardiac Tamponade |
| Implantation of multiple valves (TAV-in-TAV deployment) at 30 days | 30 days | Implantation of multiple valves (TAV-in-TAV deployment) |
| Annular rupture/dissection at 30 days | 30 days | \- Annular rupture/dissection |
| Left ventricular perforation at 30 days | 30 days | \- Left ventricular perforation |
| Conversion to open heart surgery at 30 days | 30 days | \- Conversion to open heart surgery |
| Intra-procedural mortality (during index procedure) | Procedurally | \- Intra-procedural mortality (during index procedure) |
| Procedural mortality (up to 72 hours after procedure) | Procedurally and up to 72 hours post-procedurally | \- Procedural mortality (up to 72 hours after procedure) |
| Mortality (cardiac/non-cardiac) at 30 days and 1 year | 30 days and 1 year | \- Mortality (cardiac/non-cardiac) |
| All stroke (disabling/non disabling) at 30 days and 1 year | 30 days and 1 year | \- All stroke (disabling/non disabling) |
| Composite of all-cause mortality or disabling stroke at 30 days and 1 year | 30 days and 1 year | \- Composite of all-cause mortality or disabling stroke |
| Hospitalization for valve-related symptoms or worsened congestive heart at 30 days and 1 year | 30 days and 1 year | \- Hospitalization for valve-related symptoms or worsened congestive heart failure |
| Life-threatening/major bleeding at 30 days and 1 year | 30 days and 1 year | \- Life-threatening/major bleeding (BARC 3b or more) |
| Myocardial infarction at 30 days and 1 year | 30 days and 1 year | \- Myocardial infarction |
| Valve related dysfunction requiring repeat procedure at 30 days and 1 year | 30 days and 1 year | \- Valve related dysfunction requiring repeat procedure (BAV, TAVI or SAVR) |
| New permanent pacemaker rate | 30 days | The first secondary objective is to compare the new permanent pacemaker rate at 30 days (powered for superiority). |
| Valve thrombosis at 30 days and 1 year | 30 days and 1 year | \- Valve thrombosis |
| New AV-conduction disturbances at 30 days and 1 year | 30 days and 1 year | \- New AV-conduction disturbances (LBBB only) |
| New pacemaker implantation at 1 year | 1 year | \- New pacemaker implantation at 1 year |
| Any arrhythmia resulting in hemodynamic instability or requiring therapy at 30 days and 1 year | 30 days and 1 year | Any arrhythmia resulting in hemodynamic instability or requiring therapy |
| VARC-2 combined endpoints at 30 days | 30 days | Composite of device success, early safety, clinical efficacy and time-related valve safety |
| Time-related valve safety at 1 year | 1 year | Time-related valve safety |
| Echocardiographic endpoint (1) | Post-procedurally [day 1 to 7], at 30 days, 1 year | \- Structural valve deterioration |
| Echocardiographic endpoint (2) | Post-procedurally [day 1 to 7], at 30 days, 1 year | \- Prosthetic aortic valve stenosis |
| Echocardiographic endpoint (3) | Post-procedurally [day 1 to 7], at 30 days, 1 year | \- Patient prosthesis mismatch |
| Echocardiographic endpoint (4) | Post-procedurally [day 1 to 7], at 30 days, 1 year | \- Aortic regurgitation (grading), proportion of more than mild regurgitation |
| Echocardiographic endpoint (5) | Post-procedurally [day 1 to 7], at 30 days, 1 year | \- Intended valve performance: No prosthesis mismatch, mean aortic valve gradient \<20 mmHg or peak velocity \<3 m/s, without moderate or severe prosthetic valve aortic regurgitation. |
| Echocardiographic endpoint (6) | Post-procedurally [day 1 to 7], at 30 days, 1 year | \- Systolic LV ejection fraction |
| Echocardiographic endpoint (7) | Post-procedurally [day 1 to 7], at 30 days, 1 year | \- LV diastolic function |
| Echocardiographic endpoint (8) | Post-procedurally [day 1 to 7], at 30 days, 1 year | \- Left atrial volume |
| Echocardiographic endpoint (9) | Post-procedurally [day 1 to 7], at 30 days, 1 year | \- Right ventricular (RV) dimension and function |
| Echocardiographic endpoint (10) | Post-procedurally [day 1 to 7], at 30 days, 1 year | \- Right atrial (RA) area |
| Echocardiographic endpoint (11) | Post-procedurally [day 1 to 7], at 30 days, 1 year | \- RV/RA-ratio and estimated systolic pulmonary arterial pressure |
| Endocarditis at 30 days and 1 year | 30 days and 1 year | \- Endocarditis |
Countries
Denmark, France, Germany, Italy, Spain, United Kingdom
Outcome results
None listed